enzh-TWfrdeitjaptrues

Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

Targeted Drug Found Effective as Initial Treatment for Waldenström Macroglobulinemia

Targeted Drug Found Effective as Initial Treatment for Waldenström Macroglobulinemia

When a clinical trial showed the targeted drug ibrutinib to be highly effective in patients with a form of lymphoma called Waldenström macroglobulinemia, the results were so compelling that the U.S. Food and Drug Administration approved the drug for all patients with the disease, even though the trial included only patients previously treated with other agents.

Read more..

IGM-Related Amyloidosis - by Dr. Shayna Sarosiek (The Torch, Jan 2022)

IGM-Related Amyloidosis - by Dr. Shayna Sarosiek (The Torch, Jan 2022)

The cover article for the first issue of The Torch for the new year is by Dr. Shayna Sarosiek, of the Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute. She discusses amyloidosis, its diagnosis, symptoms, and treatments. While it’s a relatively rare complication of a rare disease, it is prudent for us to be aware of it.

Read more..

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

Steven P. Treon, MD, MA, PhD, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with Waldenström macroglobulinemia with MYDD88 and CXCR4 mutations. These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

Read more..

Venclexta Demonstrates ‘Very Impressive’ Responses for Patients With Waldenström Macroglobulinemia

Venclexta Demonstrates ‘Very Impressive’ Responses for Patients With Waldenström Macroglobulinemia

Dr. Jorge J. Castillo, lead author of the study and clinical director of the Waldenström Macroglobulinemia Program at the Dana-Farber Cancer Institute in Boston, explained to CURE® that BCL2 inhibitors like Venclexta are approved by the Food and Drug Administration for other cancers such as chronic lymphocytic leukemia and acute myeloid leukemia; however, this is the first clinical trial evaluating the drug in patients with WM. He further explained that WM has malignant BCL2 cells that “immortalize” themselves, so “they are not dying when they are supposed to.”

Read more..

Updates from the IWMF Forum - Featuring Dr. Jorge Castillo

Updates from the IWMF Forum - Featuring Dr. Jorge Castillo

The International Waldenstrom’s Macroglobulinemia Forum (IWMF) recently held their annual educational forum. Jorge Castillo, MD, Clinical Director of the Bing Center for Waldenstrom Macroglobulinemia, reports on some of the important updates from the forum. Dr. Castillo discusses how bone marrow biopsies should be evaluated and the importance of genetic profiling testing. He also explains the use of BTK inhibitors and the status of certain clinical trials, including those investigating new Bcl-2 inhibitors.

Read more..

Bing-Neel Update with Dr. Jorge Castillo

Bing-Neel Update with Dr. Jorge Castillo

In November 2021, Dr. Jorge Castillo of Dana-Farber Cancer Institute (Boston, MA, US) provided a Bing-Neel update for the IWMF International Bing-Neel Specialty Topic Support Sessions.

Read more..

Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed

Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed

A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.

Read more..

Novel Treatments on the Horizon & the Importance of Clinical Trials for Drug Development

Novel Treatments on the Horizon & the Importance of Clinical Trials for Drug Development

Jorge Castillo, MD - The latest information available about potential new treatments for WM, as well as the necessity for patient participation in clinical trials to help move the pipeline along for more novel therapies.

Read more..

Ask The Doctor: Live Q&A - Dr. Tom Hoffmann, Moderating

Ask The Doctor: Live Q&A - Dr. Tom Hoffmann, Moderating

Panelists: Drs. Stephen Ansell, Jorge Castillo, Mary McMaster, Andrew Branagan, Christian Buske, and Steven Treon. A panel of WM experts will answer, and sometimes debate, questions about Waldenstrom macroglobulinemia from the IWMF 2021 Ed Forum audience.

Read more..

A Review of NCCN Guidelines for WM - Steven Treon, MD, PhD

A Review of NCCN Guidelines for WM - Steven Treon, MD, PhD

Dr. Treon will review the NCCN guidelines. NCCN is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. The NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.

Read more..